Aaron Gerds MD, MS

Aaron Gerds, MD, MS, completed his undergraduate degree, a BA in biology and chemistry, with honors at Hope College in Holland, Michigan, and obtained his MD from Loyola University Chicago Stritch School of Medicine. He continued his Internal Medicine residency at Loyola University Hospital where he served as chief resident. In Chicago, he became interested in hematology clinical trials which led him to pursue a master’s degree in clinical research methods and epidemiology. Dr. Gerds completed his hematology and oncology fellowship at the University of Washington, Fred Hutchinson Cancer Research Center, in Seattle and pursued a sub-specialty in treating patients with myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), as well as other myeloid disorders. During his fellowship, he was awarded the ASBMT’s New Investigator Award.

Dr. Gerds is an Associate Professor of Medicine at the Cleveland Clinic Taussig Cancer Institute where he serves as the principal investigator for a number of clinical trials for the treatment of MPNs and myeloid neoplasia with a focus on developing new treatments for these patients. He is also an active member of the American Society of Hematology, participating in both the Advocacy Leadership Institute and Clinical Research Training Institute, as well as serving as Chair of the Committee on Communications, as a member of the Test Materials Development Committee, former Editor of the ASH News Daily, and Senior Executive Editor of the 8th Edition of ASH-SAP. Dr. Gerds serves as the Medical Director for the Case Comprehensive Cancer Center’s Clinical Research Office and is co-PI for the Center’s LAPS grant. He is also the institutional PI for the SWOG Cancer Research Network, is part of the leadership on several national clinical trials, and is the chair of the National Comprehensive Cancer Network (NCCN) Myeloproliferative Neoplasms and Systemic Mastocytosis Guidelines.